drugset / Trial / NCT00936520
SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of SAR 1118 within the anterior and posterior chamber of the eye and plasma in subjects undergoing elective vitrectomy when treated with escalating concentrations of the study drug for approximately 1 week.
Timeline
- Start
- 2009-08
- Primary completion
- 2010-05
- Completion
- 2010-05
Outcome
Outcome not reported
Stopped: “Preliminary analysis showed little or no bioactivity.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lifitegrast | Unknown | 0.1 % | Topical |
| Subject | Lifitegrast | Unknown | 1 % | Topical |
| Subject | Lifitegrast | Unknown | 5 % | Topical |